收藏切换
Utilization analysis of monoclonal antibody drugs in sample hospitals in Shanghai from 2019 to 2021
收藏切换
Ling LEI1, Huajuan YAO1, Jiayuan QIU1, Yan YAO2, *
World Clinical Drug | 2022, 43(12) : 1620 - 1626
Less
收藏切换
World Clinical Drug | 2022, 43(12): 1620-1626
• Article •
Utilization analysis of monoclonal antibody drugs in sample hospitals in Shanghai from 2019 to 2021
Full
Ling LEI1, Huajuan YAO1, Jiayuan QIU1, Yan YAO2, *
Affiliations
  • 1.Fuzhou Medical College of Nanchang University, Fuzhou 344000, Jiangxi Province, China
  • 2.China National Pharmaceutical Industry Information Center, Shanghai 200040, China
Published: 2022-12-10 doi: 10.13683/j.wph.2022.12.017
Outline
收藏切换
Objective

By analyzing the utilization of monoclonal antibody drugs in sample hospitals in Shanghai in the past three years, the overall development of monoclonal antibody drugs was understood, so as to provide reference for clinical rational drug use.

Methods

The clinical sampling data of monoclonal antibody drugs in sample hospitals in Shanghai from 2019 to 2021 were collected from the Hospital Prescription Analysis System database of China National Pharmaceutical Industry Information Center to analyze the clinical application of monoclonal antibody drugs in the past three years.

Results

From 2019 to 2021, the number of monoclonal antibody drugs prescriptions and antitumor drugs prescriptions in sample hospitals in Shanghai increased year by year, and the prescription amount fluctuated. The trend of the number of prescriptions and the amount of prescriptions in medical institutions at all levels was basically the same. From 2019 to 2021, trastuzumab, rituximab and bevacizumab had the highest cumulative number of prescriptions and amount of prescriptions. From the market share and year-on-year analysis, it could be seen that the compound growth rate of adalimumab is the fastest, which has reached 1 200%, and pertuzumab is the second fastest, which nearly 700%, meanwhile, the market share is also relatively high, nearly 15%. In 2021, the treatment of monoclonal antibody drugs in sample hospitals in Shanghai mainly focused on anti-tumor therapy. The indications with more prescriptions of monoclonal antibody drugs for tumor treatment were breast cancer, intestinal cancer and lymphoma, respectively. The drugs with the largest number of prescriptions were trastuzumab, pertuzumab, bevacizumab, rituximab and cetuximab.

Conclusions

Monoclonal antibody drugs has been widely used in clinical practice, and the use of monoclonal antitumor drugs is occupy a dominant position.

monoclonal antibody drug  /  application analysis  /  antitumor drug
雷玲, 姚华娟, 邱家媛, 姚燕. 上海市样本医院2019年至2021年单抗类药物临床应用分析. 世界临床药物, 2022 , 43 (12) : 1620 -1626 . DOI: 10.13683/j.wph.2022.12.017
Ling LEI, Huajuan YAO, Jiayuan QIU, Yan YAO. Utilization analysis of monoclonal antibody drugs in sample hospitals in Shanghai from 2019 to 2021[J]. World Clinical Drug, 2022 , 43 (12) : 1620 -1626 . DOI: 10.13683/j.wph.2022.12.017
Year 2022 volume 43 Issue 12
11
1
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.12.017
  • Receive Date:2022-09-09
  • Online Date:2026-11-18
  • Published:2022-12-10
Article Data
Affiliations
History
  • Received:2022-09-09
Affiliations
    1.Fuzhou Medical College of Nanchang University, Fuzhou 344000, Jiangxi Province, China
    2.China National Pharmaceutical Industry Information Center, Shanghai 200040, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.12.017
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT